Last updated: August 6, 2026
Voriconazole is a mature triazole antifungal with broad generic availability, limited core-molecule exclusivity, and a formulation profile that creates targeted opportunities for excipient innovation. The strongest commercial opportunities are renal-safer parenteral delivery, pediatric and geriatric oral products, taste-masked suspensions, ready-to-use hospital presentations, and differentiated formulations for global markets.
The central excipient constraint is sulfobutyl ether beta-cyclodextrin sodium, or SBECD, in the intravenous formulation. SBECD improves voriconazole solubility but accumulates in severe renal impairment. Oral products have fewer safety constraints, but suspension palatability, sugar content, preservative use, dose measurement, and storage stability remain commercial differentiators.
What excipients are used in approved voriconazole products?
Approved voriconazole products use different excipient systems for tablets, oral suspension, and intravenous injection.
| Dosage form |
Typical strength |
Principal excipient strategy |
Commercial implication |
| Film-coated tablet |
50 mg, 200 mg |
Lactose-based direct-compression or granulation system with disintegrant, binder, glidant, and lubricant |
Low manufacturing complexity; limited differentiation |
| Oral suspension |
40 mg/mL after reconstitution |
Sucrose-based powder system with suspending agent, buffer, preservative, opacifier, and colloidal silica |
Taste, sedimentation, dosing accuracy, and sugar burden are key |
| Intravenous injection |
10 mg/mL after reconstitution |
SBECD solubilization system in a lyophilized vial |
Renal safety and alternative solubilization are the main opportunity areas |
The U.S. Vfend label identifies lactose monohydrate and conventional tablet-processing excipients in the oral solid dosage form. The oral suspension contains sucrose, xanthan gum, sodium citrate, citric acid, colloidal silicon dioxide, titanium dioxide, and sodium benzoate. The injectable product contains SBECD as the principal solubilizing excipient.[1]
Voriconazole has high oral bioavailability, reported at approximately 96% in the FDA label. That reduces the need for aggressive permeability-enhancing excipients and shifts formulation value toward palatability, dose flexibility, stability, and adherence.[1]
What excipient risks affect intravenous voriconazole?
The principal intravenous risk is SBECD exposure in patients with renal impairment.
SBECD is used because voriconazole has limited aqueous solubility at clinically useful concentrations. The resulting injectable product is practical for hospital use but carries a renal-use limitation. The FDA label recommends avoiding intravenous voriconazole in adults and children with creatinine clearance below 50 mL/min unless the benefit outweighs the risk, because the vehicle can accumulate.[1]
This creates a clear product-development target:
- Replace SBECD with a lower-risk solubilizer.
- Reduce the total excipient dose while maintaining concentration.
- Develop a more concentrated product that lowers infusion volume.
- Create a ready-to-use solution that avoids bedside reconstitution.
- Develop a lipid, polymeric, or nanodispersion system with acceptable injectability and stability.
Any alternative system must address more than solubility. It must demonstrate acceptable pH, osmolality, infusion tolerability, container compatibility, precipitation resistance after dilution, sterilization robustness, and chemical stability.
How strong is the SBECD-related differentiation opportunity?
The opportunity is technically meaningful but commercially difficult. A new parenteral product would need to show a clinically relevant advantage over inexpensive generic injection. Renal impairment is the most credible differentiation claim, but the development program would require comparative pharmacokinetic, safety, and compatibility data.
Potential excipient platforms include:
- Hydroxypropyl-beta-cyclodextrin or other cyclodextrin derivatives.
- Polyethylene glycol and ethanol cosolvent systems, subject to toxicity and infusion tolerability limits.
- Polymeric micelles.
- Lipid emulsions or nanosuspensions.
- Amorphous solid dispersions reconstituted immediately before administration.
- Co-crystal or salt-based approaches that improve aqueous solubility.
A replacement for SBECD must avoid simply transferring renal, hepatic, hemolytic, or infusion-related risk to another excipient. A patent position based only on substituting one known solubilizer for another would face substantial obviousness risk. Stronger claims would combine a specific excipient ratio with a defined concentration, stability profile, renal-exposure benefit, and clinically relevant formulation performance.
What oral suspension formulations are protected by commercial opportunity?
The oral suspension is the most accessible formulation platform for excipient-driven product differentiation.
The reference product uses a dry powder that is reconstituted to 40 mg/mL. This format supports distribution and shelf-life control, but it introduces several use problems:
- The suspension requires reconstitution before dispensing.
- Patients or caregivers must shake the product consistently.
- Dose accuracy depends on the oral syringe and sedimentation behavior.
- Voriconazole has a strong taste profile that can reduce adherence.
- The reference suspension contains sucrose and sodium benzoate.
- Reconstituted suspension stability and storage instructions complicate pharmacy handling.
Which suspension improvements have commercial value?
The strongest oral-suspension opportunities are:
| Opportunity |
Excipient approach |
Buyer value |
| Taste masking |
Ion-exchange resin, lipid coating, polymer coating, or multiparticulate technology |
Better pediatric adherence |
| Sugar reduction |
Polyol, high-intensity sweetener, or sugar-free suspending system |
Diabetes and chronic-use positioning |
| Preservative reduction |
Low-water activity powder, preservative-free packaging, or validated antimicrobial system |
Pediatric and institutional differentiation |
| Improved redispersibility |
Xanthan alternatives, cellulose derivatives, structured vehicles |
More reliable dosing |
| Higher concentration |
Optimized wetting and suspending system |
Lower administration volume |
| Ready-to-use product |
Sterile or nonsterile aqueous suspension in unit-dose packaging |
Reduced pharmacy preparation |
| Oral syringe compatibility |
Controlled particle size and rheology |
Improved dose accuracy |
A successful taste-masked product should preserve rapid release after swallowing. Excessive coating or hydrophobic excipient use can delay dissolution, reduce exposure, or create food-effect behavior. Taste masking therefore has to be validated against pharmacokinetic equivalence, not only sensory testing.
What tablet excipient strategies are available for voriconazole?
Tablet formulation is a lower-value but lower-risk opportunity. Generic tablets are relatively easy to manufacture because voriconazole has high oral bioavailability and does not require a complex delivery system.
Potential improvements include:
- Orally disintegrating tablets for patients with swallowing difficulty.
- Smaller tablets with equivalent dose strength.
- Bilayer or combination packaging for loading-dose regimens.
- Multiparticulate tablets that support dose flexibility.
- Moisture-protective packaging for humid markets.
- Lactose-free formulations for patients with excipient intolerance.
- Low-weight tablets for pediatric dose adjustment.
- Abuse-deterrent or tamper-evident packaging for institutional supply-chain control.
An orally disintegrating tablet could be commercially relevant for pediatric and geriatric patients, but it would face taste challenges. The formulation would need rapid disintegration without releasing an unacceptable bitter taste. A drug-layered multiparticulate system with a fast-dissolving outer matrix may offer stronger protection than a conventional compressed tablet.
The patent position would be stronger if it covered a defined taste-masking architecture, particle-size range, dissolution profile, and stability result. A claim directed only to an ODT containing voriconazole and a standard superdisintegrant would likely be vulnerable to prior-art and obviousness attacks.
When does voriconazole lose exclusivity?
Voriconazole has lost the exclusivity protections that supported the original Vfend launch.
| Milestone |
Date or period |
| U.S. FDA approval of Vfend |
May 2002 |
| Original new chemical entity exclusivity |
Approximately through May 2007 |
| Pediatric exclusivity extension |
Approximately six months after completion of qualifying pediatric obligations |
| Core compound patent family |
Statutory terms generally ended around 2016, subject to patent-term adjustments or extensions |
| Generic market |
Established for tablets, oral suspension, and injection |
Pfizer’s U.S. product was approved in 2002 for invasive aspergillosis, serious Scedosporium apiospermum infections, and serious Fusarium infections, with later pediatric and additional-use labeling developments.[1,2]
What is the Orange Book status of voriconazole?
The Orange Book is the relevant source for U.S. listed patents, reference-listed drug status, therapeutic-equivalence evaluations, and approved dosage forms.[3] Voriconazole has an established reference product, Vfend, and generic versions have entered the U.S. market.
The practical patent conclusion is straightforward: the original compound and product exclusivity framework does not prevent ordinary generic competition. New commercial protection would have to come from a later patentable formulation, delivery system, method of use, device, or manufacturing process.
Which companies are challenging the voriconazole reference product?
Generic competition has historically come from multiple manufacturers rather than one identifiable challenger. U.S. and international suppliers have marketed voriconazole tablets, oral suspension, and injection after the loss of core exclusivity.
The relevant competitive groups include:
- Large generic manufacturers with hospital injectable portfolios.
- Specialty generic companies focused on anti-infectives.
- Contract development and manufacturing organizations with sterile fill-finish capacity.
- Regional manufacturers supplying oral suspension and tablet products outside the United States.
- Hospital suppliers offering compounded or pharmacy-prepared alternatives where permitted.
Because generic voriconazole is mature, an entrant without formulation differentiation would compete primarily on price, supply reliability, regulatory status, and contracting access.
What patent litigation and Paragraph IV risks affect voriconazole?
The principal Paragraph IV risk is no longer the original compound patent. A new entrant would instead face potential litigation around later patents covering:
- Modified-release formulations.
- Taste-masked particles.
- Long-acting injectable systems.
- Alternative solubilizers.
- Specific excipient ratios.
- Pediatric formulations.
- Stability-enhancing packaging.
- Manufacturing processes or solid forms.
For an innovator developing a new excipient platform, patent claims should cover multiple layers:
- Composition claims covering the excipient-drug system.
- Process claims covering preparation and drying.
- Dosage-form claims covering tablet, suspension, or injection.
- Use claims tied to renal impairment, pediatric dosing, or administration conditions.
- Packaging claims where moisture, oxygen, or reconstitution stability is material.
A formulation patent should not rely solely on a list of excipients. The strongest prosecution record would connect the formulation to measurable technical effects, such as reduced SBECD exposure, improved redispersibility, reduced bitterness, preserved bioavailability, or improved stability after dilution.
How does voriconazole compare with competing antifungals?
Voriconazole competes with both triazoles and non-azole antifungals. The principal comparators include posaconazole, isavuconazole, itraconazole, amphotericin B products, and echinocandins such as micafungin and caspofungin.
| Product class |
Excipient opportunity compared with voriconazole |
| Posaconazole |
Strong oral formulation history, including delayed-release and suspension differentiation |
| Isavuconazole |
Newer product with less generic pressure but higher cost and distinct prodrug design |
| Itraconazole |
Significant solubility and formulation complexity |
| Amphotericin B |
Lipid and liposomal delivery systems create greater formulation barriers |
| Echinocandins |
Parenteral products with different solubility and reconstitution requirements |
| Voriconazole |
Mature generic market with a specific SBECD renal constraint |
Voriconazole has a commercial advantage in familiarity and broad clinical use, but a disadvantage in generic price erosion and adverse-effect monitoring. Excipient innovation must therefore solve a defined administration or safety problem rather than offer an incremental tablet reformulation.
What FDA regulatory pathway applies to a differentiated voriconazole product?
A conventional generic using the same dosage form and route would generally pursue an abbreviated pathway, including an ANDA where the product can meet reference-product requirements.[4] A materially different formulation may require:
- An ANDA with suitability for the proposed difference, if the formulation remains within the applicable generic framework.
- A 505(b)(2) application when the product relies partly on FDA findings for the reference drug but introduces a new formulation, route, dosage form, or excipient system.
- A full NDA if the product cannot rely sufficiently on the reference product’s safety and efficacy findings.
A 505(b)(2) strategy is particularly relevant for an SBECD-reduced injection, ready-to-use product, ODT, or new pediatric suspension. The regulatory value increases if the product addresses a labeled limitation or provides a meaningful administration benefit.
What manufacturing and intellectual-property barriers exist?
Sterile parenteral development has the highest barrier. The manufacturer must control endotoxin, particulate matter, extractables and leachables, container closure integrity, aseptic processing, and dilution compatibility. Lyophilization adds cycle-development and scale-up risk.
Oral suspension development has moderate barriers. The key controls are particle-size distribution, wetting, sedimentation, rheology, preservative effectiveness, reconstitution uniformity, microbial limits, and dose-delivery accuracy.
Tablet development has the lowest barrier but also the weakest margin. Manufacturers can generally source standard excipients from multiple suppliers. Commercial protection must come from a distinctive patient or institutional benefit.
Geographic opportunity varies. The renal limitation of SBECD is most relevant in markets with high hospital use and advanced renal-care populations. Sugar-free and pediatric products may have stronger positioning in markets with centralized pediatric procurement. In lower-income markets, a stable low-cost dry suspension or robust tablet may generate more value than a premium ready-to-use injection.
What licensing deals and commercial structures are available?
Voriconazole licensing opportunities are more likely to involve technology than the active ingredient. Potential structures include:
- Licensing a cyclodextrin-replacement platform to a hospital injectable manufacturer.
- Co-development of a pediatric taste-masked suspension.
- Regional licensing of a ready-to-use injectable presentation.
- Supply agreements for coated voriconazole particles or granules.
- Acquisition of a formulation patent family with a 505(b)(2) development plan.
- Contract manufacturing of sterile product for generic or specialty-pharma partners.
A platform owner should seek milestone payments linked to formulation selection, regulatory submission, approval, and commercial launch. Royalty value will depend on whether the product reduces renal restrictions, improves hospital workflow, or creates pediatric exclusivity and differentiated reimbursement.
What generic launch scenarios exist for a new voriconazole formulation?
Three launch scenarios are commercially credible:
Premium hospital injectable
The product replaces or reduces SBECD and targets patients with renal impairment. The value proposition is clinical and institutional. Success depends on comparative safety, formulary adoption, and reliable sterile supply.
Pediatric oral suspension
The product improves taste, dose accuracy, and sugar profile. This is the most practical specialty-generic opportunity. Pediatric exclusivity, where available, can increase commercial protection, but the market remains price-sensitive.
Low-cost global oral product
The product uses a robust dry suspension or tablet platform with stable supply, simple packaging, and broad geographic registration. The opportunity is volume-driven rather than margin-driven.
Key Takeaways
- Voriconazole’s core patent and regulatory exclusivity have expired, leaving generic competition established.
- The principal formulation issue is SBECD exposure in intravenous products used in renal impairment.
- A renal-safer injectable is the highest-value but most technically demanding opportunity.
- Pediatric suspension improvements in taste, sugar content, redispersibility, and dosing are commercially actionable.
- Tablet reformulation has lower development risk but limited pricing power.
- New patents should claim measurable technical effects and defined excipient architectures.
- A 505(b)(2) pathway may be appropriate for materially differentiated formulations.
- Commercial value will come from clinical risk reduction, pediatric usability, hospital workflow, or global supply economics.
FAQs
Can SBECD be removed from intravenous voriconazole?
Yes, but removal requires another system that maintains solubility, stability, injectability, and acceptable toxicology. A replacement must also remain stable after dilution into common infusion fluids.
Is a sugar-free voriconazole suspension commercially attractive?
Yes. A sugar-free product could target pediatric patients, patients with diabetes, and institutions seeking reduced sugar exposure. Its value would increase if it also improved taste and dose uniformity.
Can a voriconazole formulation receive new patent protection after generic entry?
Yes. New protection may cover a novel excipient system, dosage form, delivery platform, manufacturing process, or specific clinical use. The claims must be technically distinct and supported by unexpected or clinically relevant performance.
Would an orally disintegrating voriconazole tablet improve market access?
It could improve administration for pediatric, geriatric, and dysphagic patients. Taste masking and bioequivalence are the main development challenges.
Which voriconazole product has the greatest licensing potential?
A renal-safer intravenous formulation has the highest potential transaction value because it addresses a labeled limitation of the reference product. A pediatric taste-masked suspension is more accessible and may reach market with lower development cost.
References
-
U.S. Food and Drug Administration. (2023). Vfend (voriconazole) prescribing information. Pfizer Inc.
-
U.S. Food and Drug Administration. (2002). Vfend approval package and labeling. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. Center for Drug Evaluation and Research.
-
U.S. Patent and Trademark Office. (1999). U.S. Patent No. 5,886,220, triazole antifungal agents. U.S. Department of Commerce.
